Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Pulmonary Hypertension, May 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 171 articles: HTML format

Single Articles

1. CUI X, Zhong Y, Yin C
   A child with cobalamin C deficiency caused by complex heterozygous variation of c.567dupT and c.80A > G complicated with pulmonary arterial hypertension and hydrocephalus: A case report and literature review.
   Medicine (Baltimore). 2026;105:e48340.
   PubMed    
   Abstract available
   
   

2. DAI T, Liu B, Zhao Q, Li X, et al
   Risk factors for different types of arrhythmias and their prognostic impact in patients with heart failure and concomitant pulmonary hypertension (PH-LHF): a large-scale retrospective cohort study.
   Front Cardiovasc Med. 2026;13:1773989.
   PubMed    
   Abstract available
   
   

3. MCCORMACK C, Hardcastle SJ, Moyna NM, Morahan E, et al
   Flexible, Accessible, Effective: Patient Perceptions of the Pulmonary Hypertension and Home-Based (PHAHB) Physical Activity Intervention.
   Pulm Circ. 2026;16:e70309.
   PubMed    
   Abstract available
   
   

4. GAO L, Wu Q, Li X, Long Y, et al
   Baicalin-geniposide attenuates pulmonary inflammation and vascular injury via HMGB1 blockade: insights from a cerebral ischemia-reperfusion model and implications for pulmonary hypertension.
   Front Pharmacol. 2026;17:1822890.
   PubMed    
   Abstract available
   
   

5. YANG Y, Lei Y, Wu B, Ning K, et al
   Integrative single-cell RNA-seq and ATAC-seq analysis reveals the key role of inflammatory cell activation in pulmonary arterial hypertension.
   Front Immunol. 2026;17:1796116.
   PubMed    
   Abstract available
   
   

6. HOCKING J, Felder A, Connelly M, Dudek T, et al
   Early experience with chronic thromboembolic pulmonary hypertension in patients undergoing structured follow-up after Pulmonary Embolism Response Team evaluation.
   Proc (Bayl Univ Med Cent). 2026;39:425-430.
   PubMed    
   Abstract available
   
   

7. PENTIKAINEN MO, Heliovaara E, Halme M, Rasanen J, et al
   Chronic Thromboembolic Pulmonary Hypertension in Patients With Thoracic Outlet Syndrome-Association With Younger Age and More Distal Disease.
   Heart Lung Circ. 2026 Apr 29:S1443-9506(26)00050.
   PubMed    
   Abstract available
   
   

8. ERDAG M, Caliskan T, Yildirim H, Kivrak T, et al
   Retinal microvascular and neuroretinal structural changes in pulmonary arterial hypertension assessed by OCTA: a comparative study.
   Turk J Med Sci. 2026;56:471-478.
   PubMed    
   Abstract available
   
   

9. BECERRIL PONCE A, Cota-Arce JM, Arenas-Lugo JA, Morales-Diaz LA, et al
   Chronic Thromboembolic Pulmonary Hypertension in a Patient With Systemic Lupus Erythematosus and Antiphospholipid Syndrome: A Case of Surgical Management With Pulmonary Endarterectomy.
   Cureus. 2026;18:e106075.
   PubMed    
   Abstract available
   
   

10. MELENDRES-GROVES L, Perez VJ, Vaidya A, Lee HG, et al
    Qualitative interviews of patients with methamphetamine-associated pulmonary hypertension: Understanding the unmet medical need from the patient lens.
    JHLT Open. 2026;13:100549.
    PubMed    
    Abstract available
    
    

11. AUGER WR, Krasuski RA, Mahmud E, Leary PJ, et al
    Balloon Pulmonary Angioplasty for Treatment of Chronic Thromboembolic Pulmonary Hypertension: Statement From the BPA-CTEPH Alliance.
    JACC Cardiovasc Interv. 2026;19:923-942.
    PubMed    
    Abstract available
    
    

12. GE D, Zhang Z
    Platelet-To-Lymphocyte Ratio and 28-Day Survival in Critically Ill Patients With Pulmonary Hypertension: Insights From a MIMIC-IV Retrospective Analysis.
    Br J Hosp Med (Lond). 2026;87:52966.
    PubMed    
    Abstract available
    
    

13. FORWARD C, McCullagh B, Gaine S, Quadery SR, et al
    Update on the Diagnosis and Treatment of Chronic Thromboembolic Pulmonary Hypertension: Diagnostic Imaging and Treatment Pathways in a New Era.
    Br J Hosp Med (Lond). 2026;87:53105.
    PubMed    
    Abstract available
    
    

14. LUO J, Chang J, Liu Y, Shao Y, et al
    NDRG2 Drives DRP1 Phosphorylation to Promote the Progression of Pulmonary Hypertension.
    Front Biosci (Landmark Ed). 2026;31:48054.
    PubMed    
    Abstract available
    
    

15. LIU Q, Zhao Y, Jiang Z, Lu H, et al
    Preoperative of balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension using virtual balloon expansion: a pilot study.
    Front Bioeng Biotechnol. 2026;14:1741437.
    PubMed    
    Abstract available
    
    

16. JOSE A, Apewokin S, Ollberding NJ, Duan Q, et al
    Lactobacillus Is Associated With Disease in Pulmonary Arterial Hypertension: A Prospective Cohort Study.
    Compr Physiol. 2026;16:e70161.
    PubMed    
    Abstract available
    
    

17. AHMAD A, Zhang S, Ren Q, Li L, et al
    Integrating DeltaPCO(2) and Ca-vO(2) Into a Heart-Lung Coupling Index: A Novel Approach to Evaluate Cardiopulmonary Uncoupling in Pulmonary Arterial Hypertension.
    Compr Physiol. 2026;16:e70148.
    PubMed    
    Abstract available
    
    

18. ABDOU RM, El Wakeel MA, El-Kassas GM, Ali WH, et al
    Plasma Asymmetric Dimethylarginine as a Biomarker of Disease Severity and Therapeutic Response in Neonatal Persistent Pulmonary Hypertension: An Observational Prospective Case-Control Study.
    Clin Ter. 2026;177:539-548.
    PubMed    
    Abstract available
    
    

19. ZHANG Y, Zeng M, Guo P, Zhang Z, et al
    Effects of Rehmannia glutinosa Libosch. Rhizome water extract and Rehmapicrogenin on pulmonary hypertension: Multi-omics insights into epidermal growth factor receptor/pyruvate kinase M2 pathway and metabolic regulation.
    J Ethnopharmacol. 2026;367:121775.
    PubMed    
    Abstract available
    
    

20. STEFFES LC, Chiles KA, Masud SR, Rahman A, et al
    Excessive Postnatal Smooth Muscle Differentiation in a Lung Specific Model of TBX4-related Pulmonary Hypertension.
    JCI Insight. 2026 Apr 23:e194251. doi: 10.1172/jci.insight.194251.
    PubMed    
    Abstract available
    
    

21. COLON HIDALGO D, Lewis CV, Nguyen TN, Posey JN, et al
    R213G-Mediated Redistribution of EC-SOD Protects Against Sugen-Hypoxia Pulmonary Hypertension in Mice.
    Pulm Circ. 2026;16:e70307.
    PubMed    
    Abstract available
    
    

22. PARVATHANENI K, Kochanski JJ, Tandel MD, Liu E, et al
    Treprostinil Is Associated With Early and Sustained Improvement in Group 3 Pulmonary Hypertension and Right Ventricular Function in Children.
    Pulm Circ. 2026;16:e70304.
    PubMed    
    Abstract available
    
    

23. WALIGORA M, Zaczynska K, Stepniewski J, Lis E, et al
    Electrocardiographic signs to differentiate between chronic thromboembolic pulmonary hypertension and intermediate-high risk acute pulmonary embolism.
    Sci Rep. 2026 Apr 25. doi: 10.1038/s41598-026-48092.
    PubMed    
    
    
    

24. PLAYAN-ESCRIBANO J, Labrandero de Lera C, Albert de la Torre L, Rodriguez-Ogando A, et al
    Adapting the REVEAL Lite 2 score to the pediatric population through machine learning: insights from the REHIPED registry for pediatric pulmonary hypertension.
    Rev Esp Cardiol (Engl Ed). 2026 Apr 23:S1885-5857(26)00074.
    PubMed    
    Abstract available
    
    

25. XIE Y, Tan Y, Li J
    [Role of echocardiography in the assessment of right ventricular function in pulmonary hypertension].
    Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2026;51:150-157.
    PubMed    
    Abstract available
    
    

26. KAS F, Elhai M, Becker MO, Dobrota R, et al
    Beyond screening for pulmonary arterial hypertension: The DETECT score is a potential promising prediction tool for all-cause mortality in systemic sclerosis: Analysis from the EUSTAR database.
    J Autoimmun. 2026;160:103555.
    PubMed    
    Abstract available
    
    

27. LU T, Jia W, Wang Y, Ma Y, et al
    Therapeutic potential of 20-Hydroxyecdysone in pulmonary arterial hypertension: involvement of Mas receptor and PI3K-Akt pathway.
    Cell Mol Biol Lett. 2026;31:70.
    PubMed    
    Abstract available
    
    

28. CONSTANTINE A, Dimopoulos K, Condliffe R, Clift P, et al
    Paediatric pulmonary arterial hypertension following congenital heart defect repair: enhanced risk stratification and outcomes in a national cohort.
    Eur Heart J Qual Care Clin Outcomes. 2026;12:325-335.
    PubMed    
    Abstract available
    
    

29. GUO M, Li K, Huang Y, Wang X, et al
    NICD4/USP8-Positive Feedback Loop Contributes to the Development of Hypoxic Pulmonary Hypertension.
    Hypertension. 2026 May 8. doi: 10.1161/HYPERTENSIONAHA.125.25501.
    PubMed    
    Abstract available
    
    

30. SHAH SS, Rehman AU, Amin S, Nawaz M, et al
    Male Sex Is Associated With Severe Pulmonary Hypertension and Worse Outcome in Chronic Obstructive Pulmonary Disease Patients Referred for Right Heart Catheterization.
    Pulm Circ. 2026;16:e70317.
    PubMed    
    
    
    

31. ZHOU YP, Qiu LH, Ma W, Cao YS, et al
    Acute hemodynamic effects of TPN171H in pulmonary arterial hypertension: a randomized, controlled, phase 2a trial.
    Signal Transduct Target Ther. 2026;11:171.
    PubMed    
    Abstract available
    
    

32. DAGHER C, O'Sullivan DM, Farber HW, Parikh R, et al
    An Abbreviated Assessment Tool for Detection of Pulmonary Hypertension in Patients With Interstitial Lung Disease.
    Pulm Circ. 2026;16:e70316.
    PubMed    
    Abstract available
    
    

33. VAN RENTERGHEM E, Lekane M, Gommeren K, Merveille AC, et al
    Right and left heart morphology and function in dogs with compensated chronic right ventricular pressure overload secondary to pulmonic stenosis or precapillary pulmonary hypertension.
    Can Vet J. 2026;67:535-545.
    PubMed    
    Abstract available
    
    

34. SUGAHARA T, Kubota H, Kamitori T, Matsuda K, et al
    Successful Completion of High-Risk Neuroblastoma Therapy After Stabilization of Pulmonary Hypertension With Tadalafil.
    Pediatr Int. 2026;68:e70427.
    PubMed    
    
    
    

35. ZHANG M, Zhang J, Bu X, Ye W, et al
    Pirfenidone Attenuates Hyperoxia-induced Lung Injury and Pulmonary Hypertension in a Mouse Model of Bronchopulmonary Dysplasia in Newborn Mice.
    J Appl Physiol (1985). 2026 May 6. doi: 10.1152/japplphysiol.00001.2026.
    PubMed    
    Abstract available
    
    

36. ZHOU YP, Qiu LH, Wang PR, Wang AY, et al
    Long-Term Survival of Balloon Pulmonary Angioplasty for Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Study.
    JACC Asia. 2026 Apr 30:S2772-3747(26)00188-2. doi: 10.1016/j.jacasi.2026.
    PubMed    
    Abstract available
    
    

37. MUKHERJEE M, Bogaard HJ
    You Can't Always Get What You Want: Sensitivity or Specificity in Pulmonary Hypertension Prediction.
    JACC Asia. 2026;6:746-747.
    PubMed    
    
    
    

38. JIANG H, Loh S, Chia SY, Ruan W, et al
    Development of a Noninvasive Prediction Score for Post-Capillary Pulmonary Hypertension in a Multi-Ethnic Asian Population.
    JACC Asia. 2026;6:736-745.
    PubMed    
    Abstract available
    
    

39. LIN J, Gu X, Cai Z
    Evidence Gap and Challenges in the Management of Mild Pulmonary Hypertension.
    JACC Asia. 2026;6:733-735.
    PubMed    
    
    
    

40. OJO T, Cablay K, Emara N, Meyer A, et al
    Pulmonary Hypertension Following the Use of Trastuzumab Biosimilars.
    Case Rep Pulmonol. 2026;2026:1076907.
    PubMed    
    Abstract available
    
    

41. TRAMMELL AW, Verma D, Cruse AR, Cui X, et al
    Association of Antidiabetic Medication Classes With Survival Outcomes in Pulmonary Hypertension Patients With Diabetes.
    Pulm Circ. 2026;16:e70313.
    PubMed    
    Abstract available
    
    

42. KUSAYEV J, Nayak S, Frishman WH, Aronow WS, et al
    Long-Term Oxygen Therapy and Cardiovascular Physiology: Divergent Effects in Heart Failure and Pulmonary Hypertension.
    Cardiol Rev. 2026 May 6. doi: 10.1097/CRD.0000000000001295.
    PubMed    
    Abstract available
    
    

43. AI Z, Jia Q, Wen S, Zhu Y, et al
    Difference in risk profiles for pulmonary hypertension between non-elderly and elderly patients undergoing maintenance hemodialysis.
    BMC Nephrol. 2026 May 5. doi: 10.1186/s12882-026-05020.
    PubMed    
    Abstract available
    
    

44. GHANI H, Thillai M, Jenkins D, Bussell E, et al
    Pulmonary Blood Volumes on CT Predict Residual Pulmonary Hypertension Post-Pulmonary Endarterectomy.
    Am J Respir Cell Mol Biol. 2025 Oct 22:aanaf026. doi: 10.1093.
    PubMed    
    Abstract available
    
    

45. CORSON A, Philip R, Tailor N, Chakraborty A, et al
    Pediatric Pulmonary Hypertension: A Systematic Approach.
    JACC Case Rep. 2026 May 5:108135. doi: 10.1016/j.jaccas.2026.108135.
    PubMed    
    Abstract available
    
    

46. YANG ZT, Wang YW, Bai HJ, Pan X, et al
    Modulation of vascular remodeling and vasoconstriction by alpha-phellandrene in hypoxia-induced pulmonary hypertension.
    J Pharm Pharmacol. 2026;78:rgag046.
    PubMed    
    Abstract available
    
    

47. LIU Y, Wu Y, Yue W, Qiu X, et al
    Early venoarterial extracorporeal membrane oxygenation with airway clearance techniques in severe pertussis with pulmonary hypertension in a two-month-old infant: a case report.
    Int J Emerg Med. 2026 May 4. doi: 10.1186/s12245-026-01247.
    PubMed    
    Abstract available
    
    

48. WU Y, Zhu Y, Gao G, Li S, et al
    Identification risk factors for perinatal complications among pregnant women with pulmonary arterial hypertension.
    Hypertens Pregnancy. 2026;45:2652977.
    PubMed    
    Abstract available
    
    

49. FREDMAN ES, Allam H, Varghese NP, Kobayashi D, et al
    Transcatheter Folded Valve Placement Within a Patent Ductus Arteriosus for Pulmonary Hypertension.
    JACC Case Rep. 2026 May 4:108137. doi: 10.1016/j.jaccas.2026.108137.
    PubMed    
    Abstract available
    
    

50. YAN Y, Xu Z, Zhou Y, Wang X, et al
    Advances in the pathogenesis and clinical management of pulmonary hypertension.
    Med Rev (2021). 2026;6:120-141.
    PubMed    
    Abstract available
    
    

51. NASIR M, Bekele M, Markos S
    Reversibility of Pulmonary Hypertension and RV Dysfunction After Adenotonsillectomy in Children and Adolescents From Ethiopia.
    Sage Open Pediatr. 2026;13:30502225261442815.
    PubMed    
    Abstract available
    
    

52. REIS-FERREIRA A, Castanheira-Moreira J, Coelho-Pinho H, Mendes M, et al
    One Health Insights into Pulmonary Hypertension: Bridging Human and Canine Medicine.
    Vet Sci. 2026;13:341.
    PubMed    
    Abstract available
    
    

53. ALWAHEED AJ, Alqatari SG, Alalwan SJ, Alnufaily DA, et al
    The Role of Platelet-to-Neutrophil Ratio as a Biomarker for Pulmonary Hypertension in Sickle Cell Disease Patients: A Retrospective Cohort Study.
    Medicina (Kaunas). 2026;62:774.
    PubMed    
    Abstract available
    
    

54. TITZ A, Muller J, Schneider SR, Saxer S, et al
    Accuracy of Measuring Blood Pressure with a Volume Clamp-Based Finger Cuff vs. Arterial Line at Rest and During Exercise in Patients with Pulmonary Hypertension: A Post Hoc Analysis.
    J Clin Med. 2026;15:3033.
    PubMed    
    Abstract available
    
    

55. CHEN X, Zhou L, Zhu C, Sun Z, et al
    Integrated Bioinformatics Analysis and In Vitro Evidence Support HSP90AA1 as a Candidate Target of Camellia petelotii (Merr.) Sealy in Pulmonary Arterial Hypertension.
    Int J Mol Sci. 2026;27:3687.
    PubMed    
    Abstract available
    
    

56. SCHULZ J, Stark VC, Harbaum L, Kozlik-Feldmann R, et al
    Sotatercept in Children with Pulmonary Hypertension-A Narrative Review.
    Children (Basel). 2026;13:465.
    PubMed    
    Abstract available
    
    

57. CATALANI F, Pannunzio A, Valeriani E, Ageno W, et al
    Exploring the Association Between Pulmonary Hypertension and Cancer: A Systematic Review and Meta-Analysis.
    Biomedicines. 2026;14:876.
    PubMed    
    Abstract available
    
    

58. FAIZAN MA, Rehman T, Malik H, Hudaib M, et al
    Optimizing riociguat therapy for pulmonary hypertension: A systematic review and meta-analysis of dose variability, safety, and efficacy.
    Medicine (Baltimore). 2026;105:e46007.
    PubMed    
    Abstract available
    
    

59. SUN ZY, Lynn HS, Tuerxun A, Xuereti M, et al
    Proteomic study of high-altitude pulmonary hypertension in the Xinjiang Pamir highlanders.
    BMC Pulm Med. 2026 May 2. doi: 10.1186/s12890-026-04325.
    PubMed    
    Abstract available
    
    

60. KHOSHNAM RAD N, Lakzaei T, Abtahi H, Mohammad Alizade T, et al
    Restoring the Cardiopulmonary Unit: A Coupling-Centric Review of Pharmacotherapy in Pulmonary Vascular Disease.
    Compr Physiol. 2026;16:e70160.
    PubMed    
    Abstract available
    
    

61. WANG Y, Nuerlan D, Paizula B, Kawulijiang Y, et al
    Inflachromene attenuates monocrotaline-induced pulmonary arterial hypertension by suppressing the HMGB1-TLR4/RAGE-NF-kappaB signaling pathway.
    Int Immunopharmacol. 2026;180:116712.
    PubMed    
    Abstract available
    
    

62. MOHAMA D, Worapongsatitaya P, Celestin B, Kazmirczak F, et al
    Incident Atrial Fibrillation and Flutter in Patients With Pulmonary Arterial Hypertension: Influence of Right Ventricular Dilatation and Reduced Right Atrial Function.
    J Am Heart Assoc. 2026;15:e045587.
    PubMed    
    Abstract available
    
    

63. LACHANT DJ, Sahay S, Block R, Ossip D, et al
    Rodatristat ethyl decreases activity in pulmonary arterial hypertension: results from the ELEVATE-2 trial.
    Ann Am Thorac Soc. 2026;23:754-761.
    PubMed    
    Abstract available
    
    

64. ROJAS DA, Fonseca M, Orellana J, Henriquez M, et al
    Role of P2Y6 receptor in pulmonary arterial hypertension and vascular remodeling following cigarette smoke exposure in mice.
    Biomed Pharmacother. 2026;198:119307.
    PubMed    
    Abstract available
    
    

65. DENG S, Lao Y, Xie J, Pang Z, et al
    Rhoifolin inhibits ferroptosis and alleviates pulmonary arterial hypertension via the TNF-alpha/TNF-R1/CASP8/CASP3 pathway.
    Phytomedicine. 2026;155:158095.
    PubMed    
    Abstract available
    
    

66. GUO Q, Shao Y, Zhou W, Duan X, et al
    LGALS3BP promotes M1 polarization of macrophages and interacts with LGALS3, damaging endothelial function and exacerbating pulmonary arterial hypertension in systemic lupus erythematosus.
    Pathol Res Pract. 2026;282:156424.
    PubMed    
    Abstract available
    
    

67. ZOU J, Rao G, Hou X, Zheng Z, et al
    An integrative multi-cohort transcriptomic study reveals cell cycle- and adhesion-related hub genes as diagnostic biomarkers for pulmonary arterial hypertension.
    Adv Biol Regul. 2026;100:101145.
    PubMed    
    Abstract available
    
    

68. GENTILE F, Latrofa S, Bazan L, Barone S, et al
    Echocardiographic Estimation of Mean Pulmonary Artery Pressure: Head-to-Head Comparison of 5 Methods.
    J Am Soc Echocardiogr. 2026;39:488-496.
    PubMed    
    Abstract available
    
    

69. KIYOTA T, Mendes P, Pereira MC
    The role of the right ventricle in pulmonary arterial hypertension and imaging methods for non-invasive evaluation.
    Expert Rev Respir Med. 2026;20:543-567.
    PubMed    
    Abstract available
    
    

70. NISHIURA K, Yokokawa T, Ichimura S, Miura S, et al
    Targeting colony-stimulating factor-1 receptor attenuates the development of pulmonary arterial hypertension through C-C motif chemokine ligand 2.
    Am J Respir Cell Mol Biol. 2026;74:295-310.
    PubMed    
    Abstract available
    
    

71. LIU T, Liu X, Wang C, Zheng J, et al
    Global Burden of Pediatric Pulmonary Arterial Hypertension, 1990-2021: A Systematic Analysis from the Global Burden of Disease Study 2021.
    Pediatr Cardiol. 2026;47:2170-2181.
    PubMed    
    Abstract available
    
    

72. PANTOJA-GOMEZ OC, Agudelo-Agudelo J, Duenas-Meza E, Restrepo-Gualteros SM, et al
    Prematurity and obstructive sleep apnea in children: The perfect storm.
    Paediatr Respir Rev. 2026;58:39-44.
    PubMed    
    Abstract available
    
    

73. ZHANG M, Hu XH, Wan J
    [Progress in targeted therapy for chronic thromboembolic pulmonary hypertension].
    Zhonghua Yi Xue Za Zhi. 2026;106:1775-1780.
    PubMed    
    Abstract available
    
    

74. LIU L, Yang YH
    [Progress in targeted drug therapy for pulmonary hypertension associated with hypoxia].
    Zhonghua Yi Xue Za Zhi. 2026;106:1767-1774.
    PubMed    
    Abstract available
    
    

75. YAO H, Zhang Y
    [Advances in targeted pharmacotherapies for pulmonary hypertension associated with left heart disease].
    Zhonghua Yi Xue Za Zhi. 2026;106:1762-1766.
    PubMed    
    Abstract available
    
    

76. LUO CJ, Wang L
    [Advances in targeted therapy for pulmonary arterial hypertension].
    Zhonghua Yi Xue Za Zhi. 2026;106:1756-1761.
    PubMed    
    Abstract available
    
    

77. CUI XD, Chen JY, Wang J
    [Innovations in targeted therapies for pulmonary hypertension: advancing from vasodilation to vascular remodeling].
    Zhonghua Yi Xue Za Zhi. 2026;106:1750-1755.
    PubMed    
    Abstract available
    
    

78. LUO Q, Liu ZH
    [Current status and evolution of targeted therapy for pulmonary arterial hypertension in China].
    Zhonghua Yi Xue Za Zhi. 2026;106:1744-1749.
    PubMed    
    Abstract available
    
    

79. XIONG CM, Zhai ZG, Liu ZH
    [Thirty years of targeted drug therapy for pulmonary hypertension: the therapeutic paradigm transition from "vasodilation" to "reverse remodeling"].
    Zhonghua Yi Xue Za Zhi. 2026;106:1739-1743.
    PubMed    
    Abstract available
    
    

80. VALLELIAN F, Schaer DJ, Lechartier B, Buehler PW, et al
    Sickle cell disease-associated pulmonary hypertension: an integrated framework linking pathologies, mechanisms, and clinical phenotypes.
    EBioMedicine. 2026;128:106288.
    PubMed    
    Abstract available
    
    

81. FENG H, Lai J, Yang X, Cui X, et al
    Integrated Single-Cell Atlas Reveals Cross-Subtype Heterogeneity in Human Pulmonary Hypertension.
    Arterioscler Thromb Vasc Biol. 2026 May 14. doi: 10.1161/ATVBAHA.126.324594.
    PubMed    
    Abstract available
    
    

82. FENG J, Xia X, Li J, Wang X, et al
    Bilateral coronary artery fistulas with progressive aortic regurgitation presenting as persistent atrial fibrillation, acute heart failure and pulmonary hypertension: a case report.
    Front Cardiovasc Med. 2026;13:1776492.
    PubMed    
    Abstract available
    
    

83. JOMA M, Karam AM, Sawaf B, Sayeh W, et al
    Whipple's Disease Complicated by Severe Pulmonary Hypertension and Right Ventricular Failure.
    Eur J Case Rep Intern Med. 2026;13:006600.
    PubMed    
    Abstract available
    
    

84. MAZEPA C, Mur S, Gascoin G, Storme L, et al
    Descriptive study of the effects of treprostinil and/or epoprostenol in newborn infants with inhaled NO refractory persistent pulmonary hypertension of the newborn (PPHN).
    Therapie. 2026 Mar 18:S0040-5957(26)00047-8. doi: 10.1016/j.therap.2026.
    PubMed    
    Abstract available
    
    

85. CONDLIFFE R, Aman J, Boucly A, Cerrone E, et al
    Diagnostic and management dilemmas in pulmonary hypertension.
    Eur Respir Rev. 2026;35:250337.
    PubMed    
    Abstract available
    
    

86. CHANG WT, Lin CK, Chang CH, Lo PY, et al
    Long-term follow-up of bronchomalacia after bronchoscopy: survival and prognostic factors in dogs.
    J Vet Intern Med. 2026;40:aalag082.
    PubMed    
    Abstract available
    
    

87. HE A, Lu Y, Liu X, Liang J, et al
    Associations of Red Blood Cell Distribution Width-Derived Indicators and Their Longitudinal Dynamic Trajectories With Mortality Risk in Critically Ill Patients With Pulmonary Hypertension.
    Pulm Circ. 2026;16:e70314.
    PubMed    
    Abstract available
    
    

88. HERBERT S, Dimopoulos K, Jenkin I, Dawes TJW, et al
    Assessment of noninvasive parameters prior to diagnosis of pulmonary hypertension in patients with fibrotic interstitial lung disease.
    ERJ Open Res. 2026;12:01231-2025.
    PubMed    
    Abstract available
    
    

89. MASSALHA E, Dakka A, Marai I, Michowitz Y, et al
    Impact of pulmonary hypertension on atrial fibrillation recurrence after pulmonary vein isolation: A prospective multicenter registry study.
    Int J Cardiol Heart Vasc. 2026;64:101935.
    PubMed    
    Abstract available
    
    

90. TARRAS ES, Garcia MF, Leary PJ
    Sex Differences in Chronic Thromboembolic Pulmonary Hypertension: Beyond Biology.
    Ann Am Thorac Soc. 2026 May 12:aaoag130. doi: 10.1093.
    PubMed    
    
    
    

91. EL AMROUSY D, Koura H, Abdou N, Awny M, et al
    Hemodynamic effects of high frequency oscillatory ventilation versus conventional mechanical ventilation in term neonates with persistent pulmonary hypertension: a single-center randomized trial.
    Ital J Pediatr. 2026;52:84.
    PubMed    
    Abstract available
    
    

92. MIHAI A
    Cardiac MRI and the "lung phenotype" in pulmonary hypertension: Overlap with group 3 or distinct entity?
    Respir Med Res. 2026;89:101272.
    PubMed    
    
    
    

93. GRYNBLAT J, Eyries M, Ambar-Akkaoui M, Levy M, et al
    The preponderance of genetic variations in paediatric pulmonary hypertension.
    Respir Med Res. 2026;89:101277.
    PubMed    
    Abstract available
    
    

94. CHANG SH, Yeh FC, Chen PK, Yeo KJ, et al
    The presence of anti-Ro52/SSA antibodies may predict concomitant pulmonary hypertension and poorer survival in patients with connective tissue disease-associated interstitial lung disease.
    Clin Rheumatol. 2026 May 11. doi: 10.1007/s10067-026-08151.
    PubMed    
    Abstract available
    
    

95. LUI JK, Patel R, Luong HL, Au M, et al
    Cytokine Profiling of Systemic Sclerosis-related Pulmonary Hypertension.
    Arthritis Rheumatol. 2026 May 11. doi: 10.1002/art.70222.
    PubMed    
    Abstract available
    
    

96. GREMONT S, Ronkainen E, Kallio M
    Gap between guidelines and practice: echocardiography reporting in neonatal pulmonary hypertension.
    Cardiol Young. 2026 May 11:1-6. doi: 10.1017/S104795112611292.
    PubMed    
    Abstract available
    
    

97. SANTOSH W, Arpita M, Moreshwar BA, Parveen RS, et al
    Pediatric pulmonary hypertension registry: Single-center experience from India.
    Ann Pediatr Cardiol. 2026;19:14-22.
    PubMed    
    Abstract available
    
    

98. YON LCN, Kengni HNT, Sharau G, Nkya D, et al
    Surgical management of complex congenital heart diseases in the context of South-South cooperation: case series.
    Pan Afr Med J. 2026;53:21.
    PubMed    
    Abstract available
    
    

99. ZHU R, Liu X, Shen Y, Zhu S, et al
    Endothelial cell metabolic reprogramming and pulmonary hypertension: Research progress and therapeutic potential.
    Curr Probl Cardiol. 2026;51:103360.
    PubMed    
    Abstract available
    
    

100. BALMORI GT, Alania Torres EM, Rodriguez Pichardo YM, Utrilla AC, et al
     Reversible Dasatinib-Associated Pulmonary Hypertension Managed With Dual Therapy and Hemodynamic-Guided Withdrawal.
     JACC Case Rep. 2026 May 8:108164. doi: 10.1016/j.jaccas.2026.108164.
     PubMed    
     Abstract available
     
     

101. YAVUZ YE, Alsancak Y, Tatar S, Korucu C, et al
     TAPSE/PAi, a practical echocardiographic functional-structural index, better reflects functional severity than TAPSE/sPAP in pulmonary hypertension.
     BMC Cardiovasc Disord. 2026 May 8. doi: 10.1186/s12872-026-05920.
     PubMed    
     Abstract available
     
     

102. LU YY, Lin FJ, Chen YC, Chin CG, et al
     Bradykinin modulates endothelin-1-enhanced and monocrotaline-induced pulmonary arterial hypertension-associated arrhythmogenesis in rabbit right ventricular outflow tract via a nitric oxide-dependent pathway.
     Eur J Pharmacol. 2026;1024:178896.
     PubMed    
     Abstract available
     
     

103. MU Y, Sun J, Zhang X, Zhu H, et al
     The novel PDE5 inhibitor CPD1 attenuates pulmonary arterial hypertension through dual modulation of cGMP and TRPM8-mediated pathways.
     Bioorg Chem. 2026;177:109908.
     PubMed    
     Abstract available
     
     

104. HU Y, Wang Y, Tan W, Zhao C, et al
     Identification of Nitric Oxide-Donating Lenumlostat Derivatives with Dual Activities of Extracellular Matrix Dysregulation Inhibition and Pulmonary Vasodilation for the Treatment of Pulmonary Arterial Hypertension.
     J Med Chem. 2026;69:11448-11470.
     PubMed    
     Abstract available
     
     

105. GARCIA-CESAR M, Cueto-Robledo G, Roldan-Valadez E, Torres-Rojas MB, et al
     Management of pulmonary arterial hypertension with intermediate-high-risk pulmonary embolism during pregnancy: Diagnostic challenges, catheter-directed thrombolysis, and intravenous treprostinil - A narrative review with an institutional case snapshot
     Curr Probl Cardiol. 2026;51:103337.
     PubMed    
     Abstract available
     
     

106. FORD HJ, Chin KM, Fan F, Friberg M, et al
     Long-Term Treatment with Single-Tablet Combination of Macitentan and Tadalafil in Pulmonary Arterial Hypertension: Results from A DUE and Its Open-Label Period.
     Adv Ther. 2026;43:2106-2124.
     PubMed    
     Abstract available
     
     

107. HU J, Yao F
     Pulmonary Artery Denervation for Refractory Sjogren's Syndrome-Associated Pulmonary Arterial Hypertension: A Case Report of Combined Hemodynamic and Renal Recovery.
     Catheter Cardiovasc Interv. 2026;107:1847-1850.
     PubMed    
     Abstract available
     
     

108. WU B, Tian T, Liu Y, Qin S, et al
     The critical role of HIBCH in pulmonary arterial hypertension.
     Toxicol Appl Pharmacol. 2026;511:117779.
     PubMed    
     Abstract available
     
     

109. SHRESTHA S, Kharel S, Acharya S, Basyal G, et al
     A Retrospective Analysis of Altitude Illness at the Himalayan Rescue Association Aid Post Manang (2018-2023).
     High Alt Med Biol. 2026;27:87-92.
     PubMed    
     Abstract available
     
     

110. JIN Y, Ding L, Fan M, Kong N, et al
     Association of Vitamin Deficiency With Pulmonary Arterial Hypertension: A Review.
     Nutr Rev. 2026;84:1227-1238.
     PubMed    
     Abstract available
     
     

111. SAMARANAYAKE CB, Niglas M, Baxan N, Kempny A, et al
     Hemodynamic and metabolomic responses to infusion of GLP-1 agonist exenatide in pulmonary arterial hypertension.
     JCI Insight. 2026;11:e202660.
     PubMed    
     Abstract available
     
     

112. MA MR, Wang XK, Song X, Wang LX, et al
     When MicroRNAs meet hypoxic pulmonary hypertension.
     Biomed Pharmacother. 2026;200:119267.
     PubMed    
     Abstract available
     
     

113. MANNI R, Xhakupi H, Vani S, Bouakkaz S, et al
     A hemodynamic and biomarker study of pulmonary hypertension associated with heart failure: DISCOVER PH-HF.
     J Cardiovasc Med (Hagerstown). 2026 May 7. doi: 10.2459/JCM.0000000000001872.
     PubMed    
     Abstract available
     
     

114. GUTTE C, Grun K, Tempel L, Singerer I, et al
     Certain role of extra-domain A containing fibronectin in the development of pulmonary hypertension in the sugen/hypoxia mouse model.
     Cardiovasc Diagn Ther. 2026;16:17.
     PubMed    
     Abstract available
     
     

115. LIANG G, Yuan H, Chen S, Cheang I, et al
     Cardiac magnetic resonance-derived left heart parameters in pulmonary hypertension: diagnostic and prognostic value-a narrative review.
     Cardiovasc Diagn Ther. 2026;16:36.
     PubMed    
     Abstract available
     
     

116. SOARES LE, Alkaabneh Z, Renapurkar RD
     Small vessel disease in chronic thromboembolic pulmonary hypertension: a comprehensive narrative review of multimodality imaging evaluation.
     Cardiovasc Diagn Ther. 2026;16:32.
     PubMed    
     Abstract available
     
     

117. ADAMU BALA M, O'Connor H, Tawalbeh R, Kouritas V, et al
     Is pulmonary hypertension still a contraindication for lung volume reduction?-a narrative review of contemporary evidence.
     Ann Transl Med. 2026;14:16.
     PubMed    
     Abstract available
     
     

118. LI Z, Zhang Y, Qiu J, Tang Y, et al
     METTL3 depletion mitigates hypoxic pulmonary arterial smooth muscle cell over-proliferation via YTHDF2-dependent regulation of FOXO1 mRNA N6-methyladenosine modification: a potential mechanism of hypoxic pulmonary hypertension.
     Life Sci. 2026 May 19:124466. doi: 10.1016/j.lfs.2026.124466.
     PubMed    
     Abstract available
     
     

119. FUKUDA Y, Akagi S, Taya S, Ejiri K, et al
     Predictive value of simple echocardiographic parameters for screening pulmonary hypertension under the revised definition: a study for general hospitals.
     Open Heart. 2026;13:e004185.
     PubMed    
     Abstract available
     
     

120. JONES RJ, De Bie EMDD, Deliu N, Ng AYKC, et al
     Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension.
     Sci Transl Med. 2026;18:eads5175.
     PubMed    
     Abstract available
     
     

121. ARMSTRONG M
     Modernisation of chronic respiratory disease management: The integration of wearable technology.
     Chron Respir Dis. 2026;23:14799731261454686.
     PubMed    
     Abstract available
     
     

122. FREEMAN WJ, Rife EC, Cron RQ
     Case Report: Treatment of refractory lung disease in systemic juvenile idiopathic arthritis with cyclophosphamide and rituximab combination therapy.
     Front Immunol. 2026;17:1798455.
     PubMed    
     Abstract available
     
     

123. SLISKOVIC K, Aljughaiman A, Al Farsi A, Cheng A, et al
     Neonatal cyanosis: exploring the complexity of coexisting congenital methemoglobinaemia and pulmonary hypertension.
     BMJ Case Rep. 2026;19:e271784.
     PubMed    
     Abstract available
     
     

124. CONDE-CAMACHO R, Tuta-Quintero E, Gonzalez M, Rubiano W, et al
     Survival and Hemodynamic Effects of Parenteral Prostanoids in High-Altitude Group 1 Pulmonary Hypertension: A Retrospective Cohort Study.
     Pulm Med. 2026;2026:e2867844.
     PubMed    
     Abstract available
     
     

125. QU T, Ma K, Du Q, Zhang C, et al
     Snhg18 promotes hypoxic pulmonary hypertension by enhancing glycolysis.
     Respir Res. 2026 May 18. doi: 10.1186/s12931-026-03707.
     PubMed    
     Abstract available
     
     

126. YAGDIRAN B, Kirisci B, Cekmen N, Uslu A, et al
     The relationship between pulmonary hypertension and graft vascular resistance and rejection in liver transplant patients.
     BMC Pulm Med. 2026 May 18. doi: 10.1186/s12890-026-04351.
     PubMed    
     Abstract available
     
     

127. MADONNA R, Marra AM, Biondi F, Carbone A, et al
     Exercise pulmonary hypertension in asymptomatic patients with HIV infection Insights from the RIGHT-NET registry.
     Eur J Intern Med. 2026 May 18:106907. doi: 10.1016/j.ejim.2026.106907.
     PubMed    
     Abstract available
     
     

128. ZHOU X, Liu H, Hua Z
     A giant window-type patent ductus arteriosus with suprasystemic pulmonary hypertension: when shunt burden overrides pressure.
     Eur Heart J Case Rep. 2026;10:ytag303.
     PubMed    
     
     
     

129. DUNCAN MD
     Structured surveillance after acute pulmonary embolism can improve early detection of chronic thromboembolic pulmonary hypertension.
     Proc (Bayl Univ Med Cent). 2026;39:431-432.
     PubMed    
     
     
     

130. MCGLYNN M, Steffes LC, Shah A, Morales J, et al
     Imatinib Reduces Right Ventricular Systolic Pressure Independent of Arterial or Venous Remodeling in an Inflammatory Murine Model of Pulmonary Hypertension.
     bioRxiv [Preprint]. 2026 May 8:2026.05.05.723006.
     PubMed    
     Abstract available
     
     

131. YANG H, Cao J, Li J, Zhu L, et al
     Therapeutic Effects of Active Compounds from Poria Cocos on Pulmonary Hypertension.
     ACS Omega. 2026;11:26670-26686.
     PubMed    
     Abstract available
     
     

132. XIE Y, Wang T, Tan Y, Li J, et al
     Beyond the right ventricle: assessment of the left ventricular function in pulmonary hypertension.
     Front Med (Lausanne). 2026;13:1832363.
     PubMed    
     Abstract available
     
     

133. GUO Y, Lu S, Wang W, Huang Y, et al
     Targeted Delivery of GLUT1 Inhibitor via Macrophage Nanovesicles for Pulmonary Arterial Hypertension Therapy.
     J Extracell Vesicles. 2026;15:e70294.
     PubMed    
     Abstract available
     
     

134. DONMEZ YN, Bako D, Alpat S, Giray D, et al
     Improving Pulmonary Edema Assessment in Pediatric Congenital Heart Disease: The Role of Lung Ultrasonography.
     Arq Bras Cardiol. 2026;123:e20250322.
     PubMed    
     Abstract available
     
     

135. SINGH N, Lawson J, Ragavendran A, Banerjee S, et al
     Exploring the Lung-Liver Axis in Pulmonary Arterial Hypertension.
     Compr Physiol. 2026;16:e70171.
     PubMed    
     Abstract available
     
     

136. PRABALA P, Raza F, Chesler NC
     Heart-Lung Interactions in Pulmonary Hypertension due to Heart Failure With Preserved Ejection Fraction.
     Compr Physiol. 2026;16:e70168.
     PubMed    
     Abstract available
     
     

137. CAO VT, Van Dang H, Le HT, Nguyen HA, et al
     Longitudinal Echocardiographic Evaluation of Pulmonary Hypertension Trajectories in Infants With Bronchopulmonary Dysplasia.
     Echocardiography. 2026;43:e70504.
     PubMed    
     Abstract available
     
     

138. LOPES CARDOSO N, Santos IP, Mendes L, Torres-Castro R, et al
     Effects of physical rehabilitation interventions on pulmonary hypertension: an overview of systematic reviews of randomized controlled trials.
     Expert Rev Respir Med. 2026 May 18:1-11. doi: 10.1080/17476348.2026.2675630.
     PubMed    
     Abstract available
     
     

139. ZHU YJ, Kou JJ, Bo YC, Zhang MJ, et al
     Amonafide Targeting NTSR1-PI3K/AKT/mTOR Signaling Attenuates Vascular Remodeling in Pulmonary Arterial Hypertension.
     J Am Heart Assoc. 2026;15:e045580.
     PubMed    
     Abstract available
     
     

140. LI B, Zhu E, Wang Y, Hu Y, et al
     Identification of key driver genes in idiopathic pulmonary arterial hypertension by single-cell RNA sequencing and experimental validation.
     Biochem Biophys Res Commun. 2026;821:153869.
     PubMed    
     Abstract available
     
     

141. BOUSSEAU S, Gu S, Lahm T
     Biological and Clinical Implications of Sex Differences in Right Heart Failure Associated With Pulmonary Arterial Hypertension.
     Arterioscler Thromb Vasc Biol. 2026;46:e322096.
     PubMed    
     Abstract available
     
     

142. CHEN RN, Weng XQ, Yan Y, Chen QY, et al
     Enhanced Mitochondrial Mrs2-Mg(2+) Signaling Drives Mitochondrial Dysfunction in Pulmonary Arterial Hypertension Rats.
     Hypertension. 2026 Mar 16. doi: 10.1161/HYPERTENSIONAHA.126.25866.
     PubMed    
     Abstract available
     
     

143. DERRIDJ N, Madec D, Raisky O, Malekzadeh-Milani S, et al
     Cause of death in children with heart disease: a cohort study.
     Arch Dis Child. 2026;111:497-505.
     PubMed    
     Abstract available
     
     

144. ABU-SALEH D, Koshre GR, Piper B, Wang C, et al
     Global knockout of melanoma differentiation-associated protein 5 protects mice from chronic hypoxia/SU5416-induced pulmonary hypertension.
     Am J Physiol Lung Cell Mol Physiol. 2026 Apr 24. doi: 10.1152/ajplung.00299.2025
     PubMed    
     Abstract available
     
     

145. HIRSCH K, Horn AG, Donato AJ, Schulze KM, et al
     The right time, the right cell: the potential for precision senotherapy in pulmonary arterial hypertension.
     Am J Physiol Lung Cell Mol Physiol. 2026;330:L661-L669.
     PubMed    
     Abstract available
     
     

146. LIU Y, White RJ, Lee SW, Fauvel C, et al
     Study of risk assessment scores as surrogate endpoints in pulmonary arterial hypertension trials.
     Am J Respir Crit Care Med. 2026;212:616-624.
     PubMed    
     Abstract available
     
     

147. HILL NS, Gillies H, Chakinala MM, Feldman JP, et al
     Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertension.
     Am J Respir Crit Care Med. 2026;212:802-812.
     PubMed    
     Abstract available
     
     

148. GHIO S, Rapagnani A, Pasotti B, Alloni A, et al
     Risk stratification in chronic thromboembolic pulmonary hypertension patients after pulmonary endarterectomy. The role of brain natriuretic peptide and high-sensitivity troponin I.
     Chest. 2026 Apr 28:S0012-3692(26)00579-9. doi: 10.1016/j.chest.2026.
     PubMed    
     Abstract available
     
     

149. HIGUCHI S, Mantzios K, Kiko T, Satoh T, et al
     Comparison of Hemodynamic Responses to Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension in Japan and the Netherlands: a multicenter study.
     Chest. 2026 May 4:S0012-3692(26)00601-X. doi: 10.1016/j.chest.2026.
     PubMed    
     Abstract available
     
     

150. AZARINE A, Kasani K, Kim YW, Sakhi H, et al
     The importance of Post-Processing Methods for Assessing Right Ventricular Volumes and Function in Patients with Pulmonary Hypertension: results from the PRINCEPT study.
     Chest. 2026 May 13:S0012-3692(26)00557-X. doi: 10.1016/j.chest.2026.
     PubMed    
     
     
     

151. HON SM, Goel K, George MP, Farber HW, et al
     Evolving Representation in Pulmonary Hypertension: Recent Insights and Challenges.
     Chest. 2026;169:1313-1316.
     PubMed    
     
     
     

152. BEGHETTI M, Axelsen LN, Borissoff JI, Farhan M, et al
     A Prospective, Multicenter, Open-Label, Single-Arm Phase 2 Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Selexipag in Children With Pulmonary Arterial Hypertension.
     Chest. 2026;169:1330-1344.
     PubMed    
     Abstract available
     
     

153. QIAN J, Yang X, Wang Q, Zhao J, et al
     Association of Rare Variants in Pulmonary Arterial Hypertension-Related Genes With a Distinct Vasculopathy Phenotype and Worse Outcomes in Patients With Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension.
     Chest. 2026;169:1317-1329.
     PubMed    
     Abstract available
     
     

154. SAHAY S, Estrada RA, Griffiths M, Habib N, et al
     Evolving Concepts in Pulmonary Hypertension: Implementation challenges of the current guidelines and proceedings in the US.
     Chest. 2026 May 18:S0012-3692(26)00640-9. doi: 10.1016/j.chest.2026.
     PubMed    
     Abstract available
     
     

155. DASGUPTA A, Chen KH, Wu D, Yerramilli VS, et al
     Dynamin 2 Regulates Mitochondrial Mitotic Fission in Pulmonary Hypertension.
     Circ Res. 2026 Apr 28. doi: 10.1161/CIRCRESAHA.125.327028.
     PubMed    
     Abstract available
     
     

156. PI H, Gharib SA, Leary PJ
     A Metabolomics Roadmap to Right Ventricular Function in Pulmonary Hypertension.
     Circ Res. 2026;138:e328512.
     PubMed    
     
     
     

157. LI R, Tang Y, Ding Y, Hu P, et al
     GPRASP1 Safeguards Endothelial Aspartate Metabolism to Prevent Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction.
     Circulation. 2026 May 7. doi: 10.1161/CIRCULATIONAHA.126.079030.
     PubMed    
     Abstract available
     
     

158. SARMA S, Chin KM
     Stepping Into a New Era: Sotatercept for the Treatment of Combined Precapillary and Postcapillary Pulmonary Hypertension From Heart Failure With Preserved Ejection Fraction.
     Circulation. 2026;153:1460-1462.
     PubMed    
     
     
     

159. ZHANG Y, Bonnet S, Provencher S, Piao J, et al
     A Critical Contribution of Cardiac Myofibroblasts in Right Ventricular Failure and the Role of UCP2 SNPs in the Predisposition to RV Decompensation in Pulmonary Arterial Hypertension.
     Circulation. 2026 Mar 9. doi: 10.1161/CIRCULATIONAHA.125.078674.
     PubMed    
     Abstract available
     
     

160. PULLAMSETTI SS, Vanderpool RR, de Man F, de Jesus Perez VA, et al
     Advanced Molecular, Metabolic, and Imaging Approaches to Characterizing Right Ventricular Failure: A Scientific Statement From the American Heart Association.
     Circulation. 2026 Apr 2. doi: 10.1161/CIR.0000000000001422.
     PubMed    
     Abstract available
     
     

161. FORIS V, Cho MH, Boueiz A
     Genetic variants in pulmonary hypertension associated with chronic obstructive pulmonary disease.
     Curr Opin Pulm Med. 2026 Apr 28. doi: 10.1097/MCP.0000000000001275.
     PubMed    
     Abstract available
     
     

162. APPENZELLER P, Jeffery D, Toshner M
     Remote exercise assessment in pulmonary hypertension.
     Curr Opin Pulm Med. 2026 May 7. doi: 10.1097/MCP.0000000000001277.
     PubMed    
     Abstract available
     
     

163. JOHNSON SW, Rahaghi FN, Estepar RSJ
     The clinical relevance of chest computed tomography imaging in pulmonary hypertension associated with lung diseases.
     Curr Opin Pulm Med. 2026 May 5. doi: 10.1097/MCP.0000000000001282.
     PubMed    
     Abstract available
     
     

164. VAN DER HAVE O, Hopper RK, Kameny RJ, Tran-Lundmark K, et al
     Recent advances in the clinical management of end-stage pediatric pulmonary hypertension.
     Curr Opin Pulm Med. 2026 May 20. doi: 10.1097/MCP.0000000000001283.
     PubMed    
     Abstract available
     
     

165. RODENBURG TC, Higuchi S, Andersen S, Stilling E, et al
     Right Ventricular Adaptation after Pulmonary Endarterectomy and Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension: A comparative Cardiac MRI-Based Study.
     Eur Respir J. 2026 May 7:2502314. doi: 10.1183/13993003.02314-2025.
     PubMed    
     Abstract available
     
     

166. CAI Y, Tang H, Wei X
     Pulmonary hypertension after atrial septal defect repair.
     Heart. 2026;112:583-584.
     PubMed    
     
     
     

167. RABHA KD, Kundavaram R, Soni P, Kumar A, et al
     Prevalence and Risk Factors for Pulmonary Hypertension in Children with Sickle Cell Disease: A Prospective Observational Study from Central India.
     Indian J Pediatr. 2026 May 12. doi: 10.1007/s12098-026-06175.
     PubMed    
     
     
     

168. APPENZELLER P, Ghani H, Pepke-Zaba J
     Therapeutic decisions in chronic thromboembolic pulmonary hypertension pre- and post-intervention should be informed by multimodal risk stratification.
     J Heart Lung Transplant. 2026 Apr 30:S1053-2498(26)01874.
     PubMed    
     
     
     

169. TSOI SM, Levy PT, Abman SH, Varghese NP, et al
     Phenotyping persistent pulmonary hypertension of the newborn: recognition of its persistence across world symposium on pulmonary hypertension classifications.
     J Perinatol. 2026 May 4. doi: 10.1038/s41372-026-02704.
     PubMed    
     Abstract available
     
     

170. SHENTU J, Shi G, Chen H
     Reply: Pulmonary venous remodeling takes center stage in model of group 2 pulmonary hypertension.
     J Thorac Cardiovasc Surg. 2026 May 9:S0022-5223(26)00851.
     PubMed    
     
     
     

171. TOMONAGA Y, Lichtblau M, Ulrich S, Guler SA, et al
     Economic burden of pulmonary arterial hypertension in Switzerland.
     PLoS One. 2026;21:e0348190.
     PubMed    
     Abstract available